The global vaccine program Covax has entered into an agreement to purchase 350 million doses of the corona vaccine from the American company Novavax.
Novavax entered signed a letter of intent in February to deliver a total of 1.1 billion doses, and Thursday’s agreement is part of this effort.
Subject to regulatory approval, the doses will be delivered from the third quarter of 2021 onwards. Novavax’s vaccine requires two doses for full effect and can be stored in regular refrigerators.
Once the final tests have been completed, the vaccine must also be approved by the WHO before it can be distributed around the world by Covax.
Supporting developing countries
The remaining 750 million doses will be manufactured by the company Serum Institute in India. Their factory also contributes to the production of the AstraZeneca vaccine.
Covax was formed to help developing countries receive corona vaccines. The program is led by the World Health Organization, the vaccine alliance Gavi, and an organization working on innovation in the pandemic field.
Norway has contributed NOK 1.3 billion to the Covax collaboration.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at firstname.lastname@example.org